<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032954</url>
  </required_header>
  <id_info>
    <org_study_id>01-CBED09-02</org_study_id>
    <nct_id>NCT01032954</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)</brief_title>
  <official_title>Phase Iv Study On The Safety And Efficacy Of The Full Face Applications Of Variable Doses Of 125 To 250 Units Of A Commercial Botulinum Toxin Type A (Dysport®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label and phase IV study of full face injections of variable doses of&#xD;
      botulinum toxin type A (BT-A). As it is an open-label and not blind study, both investigator&#xD;
      and subjects will know the injection local and doses of the study drug. Patients will be&#xD;
      randomized into 3 different groups. Each group will receive a specific dose according with&#xD;
      the indication evaluated by the investigator. Six visits will be schedule in this study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      4.2 Methodology&#xD;
&#xD;
      4.2.1 Patient evaluation After providing written informed consent, subject's eligibility will&#xD;
      be assessed at a Screening Visit. The subject's general medical history will be recorded.&#xD;
      This includes demographic data, history of surgical and cosmetic procedures, dermatological&#xD;
      assessment, physical examination, and prior concomitant medications. A pregnancy test will&#xD;
      also be performed.&#xD;
&#xD;
      4.2.1.1 Severity of wrinkles&#xD;
&#xD;
      One sub-investigator will rate the wrinkles with the following validated severity scales for&#xD;
      the main areas of the face at Baseline, Week 4, Week 8, Week 16 and Week 24:&#xD;
&#xD;
        -  Clinical 0-3 score for standardized assessment of facial wrinkles in the glabella area&#xD;
           (from GLADYS study)&#xD;
&#xD;
        -  Photometric Atlas for the Assessment of Crow's Feet Severity&#xD;
&#xD;
        -  Facial Wrinkle Scale, for forehead lines (Carruthers A, et al. Dermatol Surg.&#xD;
           2003;29(5):461-7)&#xD;
&#xD;
      4.2.1.2 Standard set of photographs will be taken&#xD;
&#xD;
      At Screening , 2, 3, 4 and 5 visits, photographs will be taken:&#xD;
&#xD;
      All the photographs will be taken in a standardized photographic mode with fixed position of&#xD;
      the camera. A guideline with examples of standardized photos with delimit standardized&#xD;
      positions will be provided to the person responsible to take the photos.&#xD;
&#xD;
      In the photographs, each research subject will be identified by a tag containing a reference&#xD;
      to the study, the number of the research subject and the control date. The research subjects&#xD;
      should wash their faces before the photographic procedure to remove excess oil and all make&#xD;
      up will be removed. All the pictures will be taken at the same room and under same&#xD;
      parameters.&#xD;
&#xD;
      The photograph set consist of&#xD;
&#xD;
        -  Full face frontal view relaxed;&#xD;
&#xD;
        -  One set of photographs relaxed and contracted of each indication that patient will be or&#xD;
           was treated in this study.&#xD;
&#xD;
      At the end of the study, two independent evaluators (dermatologists) will assess before and&#xD;
      after pictures in a blinded manner. This evaluation will be done to assess the efficacy of&#xD;
      BT-A in the injected areas not assessed by the scales.&#xD;
&#xD;
      4.2.3 Groups of treatment&#xD;
&#xD;
      Subjects will be assigned to one of the three following treatment groups, according with the&#xD;
      total dose received in visit 1:&#xD;
&#xD;
        -  Group 1: 30 subjects who received 125 to 170 U of BT-A (Dysport®)&#xD;
&#xD;
        -  Group 2: 30 subjects who received 171 to 210 U of BT-A (Dysport®)&#xD;
&#xD;
        -  Group 3: 30 subjects who received 211 to 250 U of BT-A (Dysport®)&#xD;
&#xD;
      4.2.4 Reconstitution of the study product and Treatment Administration An independent,&#xD;
      experienced and registered pharmacist will be the assigned to carry through the&#xD;
      reconstitution of the products. She will prepare the dilutions and the syringes of the&#xD;
      product (DYSPORT®) immediately prior to the injections.&#xD;
&#xD;
      The dilutions of DYSPORT® 500 units per vial will be made with 2 mL of 0.9% sterile saline,&#xD;
      using 3 mL syringes and a 21 gauge needle, giving a concentration of 250 units/mL or 2.5&#xD;
      units/0.01 mL of the reconstituted product.&#xD;
&#xD;
      An experienced dermatologist in the use of botulinum toxins (principal investigator - DH)&#xD;
      will perform all the injections according to the indications and total number of units that&#xD;
      will be injected according to the treatment plan, which aims to obtain the best results. She&#xD;
      will only perform the injections and will not participate in other phases of this study.&#xD;
&#xD;
      The application of the BT-A will be made with Becton, Dickinson and Company (BD) Ultra-fine&#xD;
      II 0.3 cc syringes, with a 29 gauge needle, 0.5 cm in length (short needle).&#xD;
&#xD;
      Immediately after the application, the side effects will be verified and if needed, will be&#xD;
      registered and managed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wrinkles' Severity (Forehead)</measure>
    <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
    <description>Facial Wrinkle Scale: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wrinkles' Severity (Glabella)</measure>
    <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
    <description>GLADYS study Atlas: 0 - no wrinkles, 1 - mild wrinkles; 2 - moderate wrinkles; 3 - severe wrinkles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wrinkles' Severity (Periocular [Crow's Feet])</measure>
    <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
    <description>Photonumeric Atlas for the Assessment of Crow's Feet Severity: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Sun-induced Wrinkles</condition>
  <arm_group>
    <arm_group_label>125 to 170 IU of &quot;'Botulinum toxin' &quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with intervention of 125 to 170 IU of 'Botulinum toxin'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>171 to 210 IU of 'Botulinum toxin'</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have received 171 to 210 IU of 'Botulinum toxin'</description>
  </arm_group>
  <arm_group>
    <arm_group_label>211 to 250 IU of Botulinum toxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have received 211 to 250 U of Botulinum toxi'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin</intervention_name>
    <description>Drug: Botulinum toxin&#xD;
Indications for eligibility and total doses that will be applied in each part of the face, at visit 1:&#xD;
Upper face:&#xD;
Crow's feet wrinkles - 70 units&#xD;
Glabella - 50 units&#xD;
Forehead - 40 units&#xD;
Mid face:&#xD;
Lower eyelid - 5 units&#xD;
Nasal wrinkles - 20 units&#xD;
Malar wrinkles - 10 units&#xD;
Lower face:&#xD;
Peri-oral wrinkles - 15 units&#xD;
Asymmetric smile or gummy smile - 5 units&#xD;
&quot;Cellulitic chin&quot; - 20 units&#xD;
Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.&#xD;
Patients will be allocated in each group and receive the doses described above at visit 1. At visit 2, all the patients will receive a touch-up of a standard dose of 25 U, distributed on the treated areas according patient's needs.</description>
    <arm_group_label>125 to 170 IU of &quot;'Botulinum toxin' &quot;</arm_group_label>
    <arm_group_label>171 to 210 IU of 'Botulinum toxin'</arm_group_label>
    <arm_group_label>211 to 250 IU of Botulinum toxin</arm_group_label>
    <other_name>Dysport</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written Informed Consent;&#xD;
&#xD;
          2. Subjects aged between 30 and 60 years;&#xD;
&#xD;
          3. Skin Fitzpatrick Phototypes I to VI;&#xD;
&#xD;
          4. Subjects that never received BT-A or who had previous injections of BT-A in no more&#xD;
             than one third of the face with in the last 6 months;&#xD;
&#xD;
          5. Subjects presenting at least two indications for treatment with BT-A in each third of&#xD;
             the face;&#xD;
&#xD;
          6. Medical history and physical examination which, based on the investigator's opinion,&#xD;
             do not prevent the patient from taking part in the study and use the product under&#xD;
             investigation;&#xD;
&#xD;
          7. Subjects of childbearing age should present a negative urine pregnancy test (instant&#xD;
             test) at baseline and should be using an effective contraceptive method (oral or&#xD;
             injectable contraceptive, for at last three months, and use of preservative; subjects&#xD;
             with: hysterectomy, oophorectomy or tubal ligation);&#xD;
&#xD;
          8. Availability of the patient throughout the duration of the study (24 weeks);&#xD;
&#xD;
          9. Subjects that agree not to undergo other cosmetic or dermatological procedures during&#xD;
             the study;&#xD;
&#xD;
         10. Subjects with sufficient schooling and awareness to enable them to cooperate to the&#xD;
             degree required by the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women or women intending to become pregnant during the study;&#xD;
&#xD;
          2. Subjects participating in other clinical trials;&#xD;
&#xD;
          3. Presence of scars on the face that may interfere with the result of study;&#xD;
&#xD;
          4. Subjects with neoplastic, muscular or neurological diseases;&#xD;
&#xD;
          5. Concurrent use of treatments that affect neuromuscular transmission, such as&#xD;
             curare-like depolarizing agents, lincosamides, polymyxins, anticholinesterases&#xD;
             affecting the striated muscle and aminoglycoside antibiotics.&#xD;
&#xD;
          6. Subjects with inflammation or active infection in the face;&#xD;
&#xD;
          7. Subjects with a history of sensitivity to the components of the formula;&#xD;
&#xD;
          8. Subjects with prior history of eyelid ptosis; marked facial asymmetry, excessive&#xD;
             dermatochalasis, deep dermal scarring or thick sebaceous skin.&#xD;
&#xD;
          9. Subjects presenting myasthenia gravis, Eaton-Lambert Syndrome and motor neuron&#xD;
             diseases;&#xD;
&#xD;
         10. Subjects with coagulation disorders or using anticoagulants;&#xD;
&#xD;
         11. Subjects with known systemic autoimmune diseases;&#xD;
&#xD;
         12. Subjects clinically diagnosed anxiety disorder or any significant psychiatric disorder&#xD;
             (e.g. depression) that, in the opinion of the Evaluator, might interfere with the&#xD;
             Subject's participation in the study;&#xD;
&#xD;
         13. Subjects with a history of medical treatment non-adherence or showing unwillingness to&#xD;
             adhere to the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris M Hexsel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazilian Center for Studies in Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brazilian Center for Studies in Dermatology</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90570-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <results_first_submitted>February 22, 2012</results_first_submitted>
  <results_first_submitted_qc>August 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Botulinum Toxin</keyword>
  <keyword>Rejuvenation</keyword>
  <keyword>Facial dynamic wrinkles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>125 to 170 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the lower dose of Botulinum Toxin type A</description>
        </group>
        <group group_id="P2">
          <title>171 to 210 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the intermediate dose of Botulinum Toxin type A.</description>
        </group>
        <group group_id="P3">
          <title>211 to 250 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the higher dose of Botulinum Toxin type A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Subjects have received the lower dose of Botulinum Toxin type A, between 125 to 170 units of Botulinum Toxin type A.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Subjects have received the intermediate dose of Botulinum Toxin type A, between 171 to 210 units of Botulinum Toxin type A.</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Subjects have received the higher dose of Botulinum Toxin type A, between 211 to 250 units of Botulinum Toxin type A</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="9"/>
                    <measurement group_id="B2" value="47" spread="9"/>
                    <measurement group_id="B3" value="50" spread="9"/>
                    <measurement group_id="B4" value="48" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wrinkles' Severity (Forehead)</title>
        <description>Facial Wrinkle Scale: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
        <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
        <population>Patients in each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>125 to 170 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 125 to 170 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O2">
            <title>171 to 210 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 171 to 210 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O3">
            <title>211 to 250 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 211 to 250 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
        </group_list>
        <measure>
          <title>Wrinkles' Severity (Forehead)</title>
          <description>Facial Wrinkle Scale: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
          <population>Patients in each visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.84"/>
                    <measurement group_id="O2" value="2.66" spread="0.49"/>
                    <measurement group_id="O3" value="2.60" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.44"/>
                    <measurement group_id="O2" value="1.33" spread="0.70"/>
                    <measurement group_id="O3" value="0.93" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.75"/>
                    <measurement group_id="O2" value="2.15" spread="0.75"/>
                    <measurement group_id="O3" value="1.96" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.89"/>
                    <measurement group_id="O2" value="2.48" spread="0.68"/>
                    <measurement group_id="O3" value="2.32" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.44" spread="0.88"/>
                    <measurement group_id="O2" value="2.58" spread="0.58"/>
                    <measurement group_id="O3" value="2.48" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value threshold for significance: &lt;0.05</p_value_desc>
            <method>GLM= GENERAL LINEAR MODELS WITH REPEATED</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wrinkles' Severity (Glabella)</title>
        <description>GLADYS study Atlas: 0 - no wrinkles, 1 - mild wrinkles; 2 - moderate wrinkles; 3 - severe wrinkles</description>
        <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
        <population>Patients in each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>125 to 170 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 125 to 170 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O2">
            <title>171 to 210 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 171 to 210 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O3">
            <title>211 to 250 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 211 to 250 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
        </group_list>
        <measure>
          <title>Wrinkles' Severity (Glabella)</title>
          <description>GLADYS study Atlas: 0 - no wrinkles, 1 - mild wrinkles; 2 - moderate wrinkles; 3 - severe wrinkles</description>
          <population>Patients in each visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.67"/>
                    <measurement group_id="O2" value="2.07" spread="0.53"/>
                    <measurement group_id="O3" value="2.20" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.58"/>
                    <measurement group_id="O2" value="0.59" spread="0.50"/>
                    <measurement group_id="O3" value="0.57" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.60"/>
                    <measurement group_id="O2" value="1.12" spread="0.60"/>
                    <measurement group_id="O3" value="1.07" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.65"/>
                    <measurement group_id="O2" value="1.44" spread="0.58"/>
                    <measurement group_id="O3" value="1.31" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="0.69"/>
                    <measurement group_id="O2" value="1.66" spread="0.48"/>
                    <measurement group_id="O3" value="1.53" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P-value threshold for significance: &lt;0.05</p_value_desc>
            <method>GLM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wrinkles' Severity (Periocular [Crow's Feet])</title>
        <description>Photonumeric Atlas for the Assessment of Crow's Feet Severity: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
        <time_frame>Baseline; Week 4; Week 16; Week 20; Week 24</time_frame>
        <population>Patients in each visit.</population>
        <group_list>
          <group group_id="O1">
            <title>125 to 170 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 125 to 170 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O2">
            <title>171 to 210 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 171 to 210 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
          <group group_id="O3">
            <title>211 to 250 Units of Botulinum Toxin Type A</title>
            <description>Subjects were treated with a total dose of 211 to 250 units of Botulinum Toxin type A on facial indications in upper, middle and lower face.</description>
          </group>
        </group_list>
        <measure>
          <title>Wrinkles' Severity (Periocular [Crow's Feet])</title>
          <description>Photonumeric Atlas for the Assessment of Crow's Feet Severity: 0 - none, 1 - mild; 2 - moderate; 3 - severe</description>
          <population>Patients in each visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="0.72"/>
                    <measurement group_id="O2" value="2.41" spread="0.57"/>
                    <measurement group_id="O3" value="2.17" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.66"/>
                    <measurement group_id="O2" value="1.21" spread="0.56"/>
                    <measurement group_id="O3" value="1.27" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.59"/>
                    <measurement group_id="O2" value="1.92" spread="0.49"/>
                    <measurement group_id="O3" value="1.86" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.70"/>
                    <measurement group_id="O2" value="2.12" spread="0.44"/>
                    <measurement group_id="O3" value="2.10" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.59"/>
                    <measurement group_id="O2" value="2.10" spread="0.41"/>
                    <measurement group_id="O3" value="2.33" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>125 to 170 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the lower dose of Botulinum Toxin type A.</description>
        </group>
        <group group_id="E2">
          <title>171 to 210 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the intermediate dose of Botulinum Toxin type A.</description>
        </group>
        <group group_id="E3">
          <title>211 to 250 Units of Botulinum Toxin Type A</title>
          <description>Subjects have received the higher dose of Botulinum Toxin type A.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Doris Hexsel</name_or_title>
      <organization>Brazilian Center for Studies in Dermatology</organization>
      <phone>555130262633</phone>
      <email>cientifico@cbed.org.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

